Back

Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in chronic heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Olivier Hanon

Hospital Broca of Paris, Paris (France)

3 More presentations in this session

Presentation thumbnail
Acetazolamide as an adjunct to loop diuretics in decongesting patients with acute decompensated heart failure: a systematic review and meta-analysis
Doctor J. Interior (Quezon, PH)
Abstract Slides Video
Presentation thumbnail
Pharmacological treatments in adults with chronic heart failure: a systematic review and component network meta-analysis
Miss X. Zou (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Synthetic HRV assessment of autonomic modulation effects induced by empaglifozin added to optimized therapy in a patient with post-COVID paroxysmal atrial fibrillation-induced heart failure and normal
Assistant Professor D. Brisinda (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in chronic heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
thumbnail
Congress Presentation
Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population
thumbnail
Congress Presentation
Real-world SGLT2i prescribing in an elderly population; a tertiary centre review

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources